Our expertise in drug discovery spans multiple target classes including GPCR, ion channels, nuclear hormones, kinases and other enzymes. Our pharmacologists have many years’ experience working in cardiovascular, respiratory, CNS, urogenital and immune inflammation therapeutic areas. We can set up integrated screening cascades to expedite lead discovery and optimisation. We can also validate cell- based and non cell-based assays for primary pharmacology screening and mechanism of action.
Our teams have a strong background in assay development and optimisation of target based and phenotypic screens on electrophysiology platforms. We can access human derived IPSc stem cells for the development of translationally relevant assays.
We believe it is this integration of pharmacology, ADMET and DMPK that is so important for the development of PK/PD relationships.